ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EDEN Eden Research Plc

4.40
0.00 (0.00%)
05 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.40 4.30 4.50 4.40 4.40 4.40 291,809 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -10.48 23.47M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.40p. Over the last year, Eden Research shares have traded in a share price range of 3.675p to 8.90p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £23.47 million. Eden Research has a price to earnings ratio (PE ratio) of -10.48.

Eden Research Share Discussion Threads

Showing 15876 to 15894 of 18350 messages
Chat Pages: Latest  638  637  636  635  634  633  632  631  630  629  628  627  Older
DateSubjectAuthorDiscuss
12/10/2023
13:20
The future is hard to see if you can't see Syngenta

Si tan solo uno lo hubiera resuelto

supersonico
12/10/2023
13:00
Canary told you so..

Robin Monotti
@robinmonotti

Angus Dalgleish: Professor of Oncology at St George's Hospital Medical School, London: "At the end of last year I reported that I was seeing melanoma patients who had been stable for years relapse after their first booster (their third injection). I was told it was merely a coincidence and to keep quiet about it, but it became impossible to do so. The number of my patients affected has been rising ever since. I saw two more cases of cancer relapse post booster vaccination in my patients just this last week.
Other oncologists have contacted me from all over the world including from Australia and the US. The consensus is that it is no longer confined to melanoma but that increased incidence of lymphomas, leukaemias and kidney cancers is being seen after booster injections. Additionally my colorectal cancer colleagues report an epidemic of explosive cancers (those presenting with multiple metastatic spread in the liver and elsewhere). All these cancers are occurring (with very few exceptions) in patients who have been forced to have a Covid booster whether they were keen or not, for many so they could travel.
So why are these cancers occurring? T cell suppression was my first likely explanation given that immunotherapy is so effective in these cancers. However we must also now consider DNA plasmid and SV40 integration in promoting cancer development, a feature made even more concerning by reports that mRNA spike protein binds p53 and other cancer suppressor genes. It is very clear and very frightening that these vaccines have several elements to cause a perfect storm in cancer development in those patients lucky enough to have avoided heart attacks, clots, strokes, autoimmune diseases and other common adverse reactions to the Covid vaccines.

supersonico
12/10/2023
12:28
I moved out of VRS into this .Sadly the "out of" bit was correct.The future is possibly not ours to see ?As yet.Que sera sera When it comes to compare contrast I want the contrast at the CEO integrity level.
alchemy
10/10/2023
19:10
I'm sure you're right . How long will it take ?
alchemy
10/10/2023
19:09
You've stated that about a million times and not been right yet.
kittybiscuits
10/10/2023
17:29
ROTFLMAO!

The market and share price treats the above excrement with the respect it merits.

RENEWED RESTATED RECALCULATED TARGET PRICE
EDEN RESEARCH PLC (LSE:EDEN)
0.000000 PENCE

neutralpov
10/10/2023
16:13
Ah, I see Eden got a bit of coverage with vox markets.

Corrected my typo

attyg
10/10/2023
12:29
Atty,

Might be something related to Italy , Germany or Syngenta.

Those are my guesses.

supersonico
10/10/2023
08:48
Some it up?
attyg
09/10/2023
21:18
Well , from now on , "orders not crutches ".
alchemy
09/10/2023
17:03
Eden Research raises £9.9mln and secures first commercial Ecovelex order
supersonico
09/10/2023
10:44
Neuts, There is definitely a 4th type of investor here.
timbo_slice
09/10/2023
10:13
* WARNING TO ANY POTENTIAL INVESTORS IN THIS PILE OF POO *

There are only three types of posters here:

- Paid stinkos rampers. If you don't understand that fully, you shouldn't be here.

- Unpaid desperate trapped sucker rampers, trying to engineer a spike (pump) and exit (dump) to extricate themselves from their own past idiocy.

- ravennna23 and myself.

YOU HAVE BEEN WARNED.

WALK AWAY.

NOW.

If you have a biotech addiction, consider in investing in CORTEVA, which will end up one way or another and for a song the invertebrate-torturing IP the rampers keep blathering on about.

;D

neutralpov
09/10/2023
09:03
A question I have regards Ecovelex EUA.

The Brightmaize blogger Charlie Dolphin has Blogged every September for the last three years but this year it looks to have been delayed.

Delayed for what reason Super ?I hear you ask.

Delayed for the Ecovelex EAU perhaps with Charlie Dolphin being made an insider.

AWGATWT.

supersonico
09/10/2023
08:22
My wild guess is Corteva are testing Eden tech here and the 10x French commentary from Smith will soon be applied to Spain and Italy. I also note that this Corteva post is again liked by several Syngenta staff including

Yannis Athanasopoulos .Head Biologicals Marketing & Business Development EAME at Syngenta.

George Pontikas
Business Area Head Mediterranean - President & Managing Director at Syngenta Hellas AEBE

Kostas Ikonomidis
CP Marketing and Technical Head BA Mediterranean at Syngenta
..........
Gerasimos Nikolopoulos

Biologicals Leader South Europe at Corteva Agriscience


Biologicals trials July 2023, Spain & Italy.
S. Europe team is getting experience on Corteva’s innovative pipeline in the field !

supersonico
06/10/2023
21:59
Canary told you so ..but it's way worse.

COVID Vaccine DNA Contamination, the Monkey Virus SV40 Cancer Promoter, and What’s Actually in the Vaccines

supersonico
06/10/2023
09:44
Igor Teslenko
President Europe, Middle East,

'The fresh culture, the strong focus on our partners and the freedom that I have to drive our business, are the key points that excite me the most.' As Leonardo C. takes the helm as Corteva's EMEA Seed Applied Technologies Leader, he shares insights on #LifeatCorteva and what makes it such a unique and dynamic work environment.

He informs European Seed about current business strategies, centred on Corteva listening to and responding to customers' needs with market-leading innovations that achieve results while meeting sustainability criteria, aligning with the EU Green Deal requirements.

Congratulations, Leonardo, on a well-deserved promotion! Read more about our new leader here:
Seed World Europe | Issue 3 (european-seed.com)

supersonico
06/10/2023
09:27
Was refering to your post no.15448
Re link on Corteva website.

babysitter
06/10/2023
09:11
babysitter,

I'm not sure what you mean. Do you mean that ADVFN will make it clickable? After a request to them to do so?

weyweyumfozo
Chat Pages: Latest  638  637  636  635  634  633  632  631  630  629  628  627  Older

Your Recent History

Delayed Upgrade Clock